The Norwegian court ruled Krka infringed the patent because the drug contained an optical purity above 98 percent, the Novo mesto, Slovenia-based company said in a regulatory statement today. Krka said it was ordered to pay AstraZeneca about 1.9 million euros ($2.5 million) to compensate for lost profit from the reflux drug.
Krka said it will appeal the decision.
To contact the reporter on this story: Boris Cerni in Ljubljana at firstname.lastname@example.org
To contact the editor responsible for this story: James M. Gomez at email@example.com